A hepatitis B virus transgenic mouse model with a conditional, recombinant, episomal genome
Robert L. Kruse,
Mercedes Barzi,
Xavier Legras,
Francis P. Pankowicz,
Nika Furey,
Lan Liao,
Janming Xu,
Beatrice Bissig-Choisat,
Betty L. Slagle,
Karl-Dimiter Bissig
Affiliations
Robert L. Kruse
Center for Cell and Gene Therapy, Texas Children’s Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA; Center for Stem Cells and Regenerative Medicine, Baylor College of Medicine, Houston, TX, USA; Translational Biology and Molecular Medicine Program, Baylor College of Medicine, Houston, TX, USA; Medical Scientist Training Program, Baylor College of Medicine, Houston, TX, USA
Mercedes Barzi
Department of Pediatrics, Division of Medical Genetics, Duke University, Durham, NC, USA; Y.T. and Alice Chen Pediatric Genetics and Genomics Research Center, Duke University, Durham, NC, USA
Xavier Legras
Department of Pediatrics, Division of Medical Genetics, Duke University, Durham, NC, USA; Y.T. and Alice Chen Pediatric Genetics and Genomics Research Center, Duke University, Durham, NC, USA
Francis P. Pankowicz
Center for Cell and Gene Therapy, Texas Children’s Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA; Center for Stem Cells and Regenerative Medicine, Baylor College of Medicine, Houston, TX, USA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA
Nika Furey
Center for Cell and Gene Therapy, Texas Children’s Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA; Center for Stem Cells and Regenerative Medicine, Baylor College of Medicine, Houston, TX, USA; Department of Pediatrics, Division of Medical Genetics, Duke University, Durham, NC, USA; Y.T. and Alice Chen Pediatric Genetics and Genomics Research Center, Duke University, Durham, NC, USA
Lan Liao
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA
Janming Xu
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA
Beatrice Bissig-Choisat
Center for Cell and Gene Therapy, Texas Children’s Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA; Center for Stem Cells and Regenerative Medicine, Baylor College of Medicine, Houston, TX, USA; Department of Pediatrics, Division of Medical Genetics, Duke University, Durham, NC, USA; Y.T. and Alice Chen Pediatric Genetics and Genomics Research Center, Duke University, Durham, NC, USA
Betty L. Slagle
Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA
Karl-Dimiter Bissig
Center for Cell and Gene Therapy, Texas Children’s Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA; Center for Stem Cells and Regenerative Medicine, Baylor College of Medicine, Houston, TX, USA; Translational Biology and Molecular Medicine Program, Baylor College of Medicine, Houston, TX, USA; Department of Pediatrics, Division of Medical Genetics, Duke University, Durham, NC, USA; Y.T. and Alice Chen Pediatric Genetics and Genomics Research Center, Duke University, Durham, NC, USA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA; Duke Center for Virology, Duke University, Durham, NC, USA; Duke Cancer Institute, Duke University, Durham, NC, USA; Corresponding author. Address: Department of Pediatrics, Division of Medical Genetics, Duke University, 905 South LaSalle St., Durham, NC, 27708, USA.
Background & Aims: Development of new and more effective therapies against hepatitis B virus (HBV) is limited by the lack of suitable small animal models. The HBV transgenic mouse model containing an integrated overlength 1.3-mer construct has yielded crucial insights, but this model unfortunately lacks covalently closed circular DNA (cccDNA), the episomal HBV transcriptional template, and cannot be cured given that HBV is integrated in every cell. Methods: To solve these 2 problems, we generated a novel transgenic mouse (HBV1.1X), which generates an excisable circular HBV genome using Cre/LoxP technology. This model possesses a HBV1.1-mer cassette knocked into the ROSA26 locus and is designed for stable expression of viral proteins from birth, like the current HBV transgenic mouse model, before genomic excision with the introduction of Cre recombinase. Results: We demonstrated induction of recombinant cccDNA (rcccDNA) formation via viral or transgenic Cre expression in HBV1.1X mice, and the ability to regulate HBsAg and HBc expression with Cre in mice. Tamoxifen-inducible Cre could markedly downregulate baseline HBsAg levels from the integrated HBV genome. To demonstrate clearance of HBV from HBV1.1X mice, we administered adenovirus expressing Cre, which permanently and significantly reduced HBsAg and core antigen levels in the murine liver via rcccDNA excision and a subsequent immune response. Conclusions: The HBV1.1X model is the first Cre-regulatable HBV transgenic mouse model and should be of value to mimic chronic HBV infection, with neonatal expression and tolerance of HBV antigens, and on-demand modulation of HBV expression. Lay summary: Hepatitis B virus (HBV) can only naturally infect humans and chimpanzees. Mouse models have been developed with the HBV genome integrated into mouse chromosomes, but this prevents mice from being cured. We developed a new transgenic mouse model that allows for HBV to be excised from mouse chromosomes to form a recombinant circular DNA molecule resembling the natural circular HBV genome. HBV expression could be reduced in these mice, enabling curative therapies to be tested in this new mouse model.
